Did Invivyd beat or miss consensus estimates last quarter?

What guidance did Invivyd's management provide for the next earnings period?

What were the key takeaways from Invivyd's earnings call?

What is the revenue and EPS growth rate for Invivyd year over year?

What is Invivyd's gross profit margin?

What is Invivyd's latest dividend and current dividend yield?

What does Invivyd do and what are its main business segments?

What were the key takeaways from Invivyd’s earnings call?

- **Clinical Momentum**: VYD2311 trial on track with potential resize in April; RSV antibody shows competitive potential; measles program update expected in H1 2026.
- **Commercial Strength**: PEMGARDA revenue up 31% QoQ, 77% reorder rate, and 15,000+ GPO sites highlight strong provider adoption.
- **Financial Stability**: $226.7M cash post-$200M funding, supporting mid-2026 VYD2311 data readout.
- **Strategic Expansion**: Targeting broader populations with next-gen antibodies, including pediatric and outbreak use cases.

**【Management Opening Remarks】**
- Katie Falzone introduced the call, noting the availability of the press release and presentation slides. She emphasized forward-looking statements and associated risks, advising investors to review SEC filings for risk factors.

**【CEO Summary Section】**
- **Revolution Clinical Program**: The DECLARATION trial for VYD2311 reached target enrollment, with over 1,770 participants. The IDMC recommended放宽 enrollment criteria for women and removed safety visits, indicating strong safety data. The trial may resize in April if event rates are lower than expected, with potential timing adjustments.
- **PEMGARDA Growth**: Q4 2025 net revenue grew 31% QoQ and 25% YoY, reflecting expanded use in immunocompromised populations. The reorder rate was 77%, with 15,000+ contracted GPO sites.
- **New Antibodies**: A highly potent RSV antibody was identified, competitive with existing treatments. The measles program is expected to update in H1 2026, targeting outbreak prophylaxis and pediatric use cases.

**【Chief Commercial Officer (Tim Lee) Update】**
- **Market Expansion**: PEMGARDA adoption is growing across hematology, oncology, and neurology. The team is educating clinicians on antibody benefits, with Lindsey Vonn as a spokesperson to highlight proactive immune support.
- **Commercial Infrastructure**: 15,000+ GPO sites and high reorder rates demonstrate strong provider confidence in the platform.

**【CFO Financial Commentary】**
- **Q4 2025 Financials**: Net revenue $53.4 million for the year, with $226.7 million in cash post-$200 million funding. PEMGARDA net revenue up 31% QoQ and 25% YoY, driven by expanded use.
- **Capital Position**: Sufficient liquidity to support VYD2311 pivotal data in mid-2026 and beyond, contingent on PEMGARDA growth.

**【Q&A Highlights】**
- **Declaration Trial Resizing**: Prespecified algorithm may add 30% of participants if lower-than-expected efficacy. Secondary endpoints include viral load and healthcare utilization, though powered for symptomatic COVID reduction.
- **Measles Antibody Use Cases**: Outbreak prophylaxis, pediatric bridge therapy, and vaccine enhancement. Early data suggests potential for broad use in unvaccinated or immunocompromised populations.
- **RSV Competition**: New antibody addresses evolutionary drift and known liabilities of existing treatments, positioning for differentiation.
- **Myocarditis Monitoring**: Focused on clinical events, with potential for deeper analysis if signals emerge.


Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript

- **$87M Capital Raise**: Funds pivotal VYD2311 trial, positioning for mid-2026 data readout.
- **41% YoY Revenue Growth**: PEMGARDA adoption drives Q3 financial performance.
- **Innovative Regulatory Path**: First-ever combination of mRNA vaccine and monoclonal antibody in single study.
- **Blockbuster Potential**: $3.8B annual COVID vaccine market with high patient demand for safer alternatives.
- **Pipeline Momentum**: RSV and measles programs targeting unmet needs with novel mechanisms.

**【CEO Summary Section】**
- **Turning Point in Q3**: Received FDA feedback on VYD2311, raising $87 million to fund pivotal clinical program. 
- **Clinical Timeline**: LIBERTY study to initiate by end-2025, with top-line data expected mid-2026.
- **Strategic Differentiation**: Antibody-based approach offers safety advantages over mRNA vaccines, with no inflammation-inducing mechanism.
- **Market Opportunity**: $3.8B annual U.S. COVID vaccine sales, but high patient preference for alternative prevention methods.

**【CFO Financial Commentary】**
- **Revenue Growth**: Q3 2025 revenue up 11% QoQ and 41% YoY, driven by PEMGARDA adoption.
- **Cash Position**: $87M raised in Q3, with ATM exhausted at favorable prices, providing liquidity through 2026.
- **Operational Discipline**: Maintaining cost control while scaling commercial infrastructure for VYD2311 launch.

**【Q&A Highlights】**
- **PEMGARDA Strategy**: No plans to sunset PEMGARDA; it remains a differentiated therapy for immunocompromised patients.
- **FDA Coordination**: LIBERTY study requires coordination between CBER (vaccines) and CDER (monoclonal antibodies), a novel regulatory approach.
- **Commercial Expansion**: Scaling field presence and digital engagement to prepare for VYD2311 launch, targeting broader patient population.
- **Pipeline Development**: Early-stage RSV and measles programs focus on resistance profiles and biophysical differentiation, with updates expected by year-end.

Invivyd, Inc. (IVVD) Q3 2025 Earnings Call Transcript

- **Commercial Turnaround**: Internalized salesforce driving Q2 2025 revenue surge (largest week/day in company history). 
- **Financial Discipline**: 15% QoQ opex reduction to $27.4M; targeting breakeven by mid-2025 with $48M cash. 
- **Pipeline Expansion**: 10x more potent VYD2311 vs. pemivibart; measles program launched amid 159 U.S. deaths in 2024. 
- **Regulatory Focus**: FDA decline for treatment EUA but VYD2311 shows >100x potency; engaging new FDA on transparency.

**【CEO Summary Section】**
- Transitioned to an internal commercial team in Q1 2025, targeting near-term breakeven and revenue growth. Leading indicators for PEMGARDA adoption are promising. 
- Expanded R&D pipeline into measles and RSV, with potential for best-in-class monoclonal antibodies. 
- Secured $30M non-dilutive capital through SVB term loan, supporting disciplined capital allocation.

**【CFO Financial Commentary】**
- Q1 2025 net product revenue: $11.3M (down from Q4 2024 due to salesforce transition). 
- Operating expenses reduced 15% QoQ to $27.4M, driven by cost optimization. 
- Cash balance: $48M as of March 2025, with $30M SVB facility available. 
- Targeting profitability by mid-2025 with internalized salesforce momentum.

**【Commercial Progress】**
- Replaced contract reps with 25+ internal specialists, expanding reach to 880+ infusion sites. 
- Q2 2025 showing strong momentum: largest single day and week of sales in company history. 
- Price increase (3/2025) reflects value for immunocompromised patients, with CMS update pending.

**【R&D & Clinical Updates】**
- VYD2311 (next-gen COVID antibody) shows 10x potency vs. pemivibart, with Phase 1 data expected soon. 
- Measles program launched in response to rising U.S. measles deaths (159 in 2024 vs. 45 from avian flu). 
- RSV program targeting high-value monoclonal antibody with potential blockbuster potential.

**【Regulatory & EUA Update】**
- FDA declined treatment EUA expansion for pemivibart due to immunobridging uncertainty, but VYD2311 shows >100x adintrevimab potency. 
- Engaging new FDA leadership on transparency and potential accelerated approval pathways. 
- Maintaining EUA for prevention with unique clinical efficacy data vs. competitors.

Actual	-0.18	-0.98	-0.77	-0.93	-0.47	-0.42	-0.41	-0.32	-0.46	-0.36	-0.67	-0.38	-0.4	-0.51	-0.15	-0.14	-0.12	-0.06	0.02
Forecast	-0.795	-0.735	-1.02	-0.62	-0.53	-0.4425	-0.36	-0.345	-0.37	-0.505	-0.435	-0.4667	-0.3733	-0.3375	-0.2	-0.03	-0.0043	-0.08	-0.0833
Surprise	+77.36%	-33.33%	+24.51%	-50.00%	+11.32%	+5.08%	-13.89%	+7.25%	-24.32%	+28.71%	-54.02%	+18.58%	-7.15%	-51.11%	+25.00%	-366.67%	-2690.70%	+25.00%	+124.01%

Actual	0	--	0	0	0	0	0	0	0	0	0	0	2.26M	9.30M	13.80M	11.30M	11.79M	13.13M	17.20M
Forecast	0	0	0	0	0	0	0	0	0	0	0	0	5.00M	27.25M	13.57M	34.45M	25.99M	13.10M	17.20M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-54.72%	-65.87%	+1.72%	-67.19%	-54.65%	+0.24%	0.00%

IVVD

IVVD fundamentals

IVVD Q4 2025 Earnings

Earnings Call

You can ask Aime

IVVD

IVVD fundamentals

IVVD Q4 2025 Earnings

Earnings Call

IVVD Earnings Call Summary for Q4/20258:30 AM on Mar 5, 2026

IVVD Earnings Call Summary for Q3/20258:30 AM on Nov 6, 2025

IVVD Earnings Call Summary for Q2/20258:30 AM on Aug 13, 2025

IVVD Earnings Call Summary for Q1/20258:30 AM on May 15, 2025

IVVD Earnings Call Summary for Q4/2024 Apr 1, 2026

You can ask Aime